FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

1. Name and Address of Reporting Person* GONZALEZ RICHARD A			2. Issuer Name and Ticker or Trading Symbol <u>AbbVie Inc.</u> [ABBV]		tionship of Reporting Per all applicable) Director	10% Owner	
(Last) 1 N. WAUKEO	(First) GAN ROAD	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/20/2014	- X	Officer (give title below) Chairman of the Bo	Other (specify below) ard and CEO	
(Street) NORTH CHICAGO	IL	60064	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filin Form filed by One Rep Form filed by More tha Person	porting Person	
(City)	(State)	(Zip)			1 013011		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)	ction	4. Securities A Disposed Of (D			Securities Beneficially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(11311.4)
Common stock, \$0.01 par value	02/20/2014		Α		162,960 ⁽¹⁾	Α	\$0.00	447,013	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative 3. Transaction Date 3A. Deemed Execution Date, 5. Number of Derivative 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities 8. Price of Derivative 9. Number of derivative 11. Nature of Indirect 10. Ownership Conversion Trans ction Security or Exercise (Month/Day/Year) if anv Code (Instr. Securities (Month/Day/Year) Underlying Security Securities Form: Beneficial 8) Acquired (A) or Disposed Derivative Sec (Instr. 3 and 4) (Instr. 3) Price of (Month/Day/Year) Security (Instr. 5) Beneficially Direct (D) Ownership (Instr. 4) Derivative Owned or Indirect of (D) (Instr. 3, 4 and 5) (I) (Instr. 4) Security Following Reported Transaction(s) Δm

				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(instr. 4)		
Option (right to buy) ⁽²⁾	\$51.42	02/20/2014		Α		281,030		02/20/2015	02/19/2024	Common stock	281,030	\$0	281,030	D	
Evaluation of Pashonses															

Explanation of Responses

1. These securities represent performance vested restricted stock awards under the AbbVie 2013 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon AbbVie reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

2. Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exerciseable in annual increments of 93,677 on 02/20/2015, 93,676 on 02/20/2016, and 93,677 on 02/20/2017.

Steven L. Scrogham, attorney-

in-fact for Richard A. Gonzalez

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.